一些乳腺癌是由激素失衡引起的，例如雌激素和孕激素。这些激素在引导癌细胞生长方面发挥作用。激素受体阳性乳腺癌中的激素受体会导致乳腺细胞失控增生。由于多药耐药性（MDR）、非特异性靶向作用和严重不良反应等挑战，癌症治疗如激素治疗、靶向治疗和放射治疗仍然不令人满意。新型芳香化酶抑制剂埃罗曲唑（Exe）在乳腺癌治疗中显示出有希望的疗效。本研究旨在利用DSPC、PF68和橄榄油作为脂质、表面活性剂和油相来开发和优化Exe负载的脂质纳米囊（LNCs），并加以表征。制备的纳米囊经过体外细胞培养和体内动物模型的研究。与药物相比，在MCF-7细胞系中，LNCs表现出细胞毒性，并在DMBA诱导的动物模型中显示出增强的抗癌活性和减少的心脏毒性。此外，体内药代动力学研究显示，与Exe悬浮液相比，口服Exe负载的LNCs具有4.2倍的口服生物利用度提高。本研究证明，Exe负载的LNCs的口服给药对于抗雌激素活性的埃罗曲唑在乳腺癌治疗中有很大前景。

Some breast cancers are caused by hormonal imbalances, such as estrogen and progesterone. These hormones play a function in directing the growth of cancer cells. The hormone receptors in hormone receptor-positive breast cancer lead breast cells to proliferate out of control. Cancer therapy such as hormonal, targeted, radiation is still unsatisfactory because of these challenges namely multiple drug resistance (MDR), off-targeting, severe adverse effects. A novel aromatase inhibitor exemestane (Exe) exhibits promising therapy in breast cancer. This study aims to develop and optimize Exe-loaded lipid nanocapsules (LNCs) by using DSPC, PF68 and olive oil as lipid, surfactant and oil phase, respectively and to characterize the same. The prepared nanocapsules were investigated via in vitro cell culture and in vivo animal models. The LNCs exhibited cytotoxicity in MCF-7 cell lines and enhanced anti-cancer activity and reduced cardiotoxicity in DMBA-induced animal model when compared to the drug. Additionally, in vivo pharmacokinetics revealed a 4.2-fold increased oral bioavailability when compared with Exe suspension. This study demonstrated that oral administration of Exe-loaded LNCs holds promise for the antiestrogenic activity of exemestane in breast cancer.